Data / Drug companies / Bortezomib
Bortezomib: 26 companies and 33 products in the FDA NDC directory
Bortezomib is listed in the FDA National Drug Code Directory by 26 companies, with 33 products in commercial distribution. 26 of the products (78.8%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, powder, lyophilized, for solution; injection, and the newest product started marketing on May 1, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 26
- Products
- 33
- Generic (ANDA) products
- 26 (78.8%)
- Application numbers
- 19
- Routes
- Intravenous, Subcutaneous
- Brand names
- Boruzu, Velcade
- openFDA record search
- api.fda.gov
Companies that list bortezomib
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| BluePoint Laboratories | 3 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 31, 2022 |
| Hospira, Inc. | 3 | injection, powder, lyophilized, for solution | New drug applications (NDA) | July 27, 2022 |
| Eugia US LLC | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 2, 2022 |
| Gland Pharma Limited | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 6, 2026 |
| Maia Pharmaceuticals, Inc. | 2 | injection | New drug applications (NDA) | August 11, 2022 |
| Amneal Pharmaceuticals LLC | 1 | injection | New drug applications (NDA) | September 27, 2024 |
| Apotex Corp. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 2, 2022 |
| Avenacy, LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 1, 2026 |
| Camber Pharmaceuticals, Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 3, 2024 |
| Dr. Reddy's Laboratories Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 26, 2022 |
| Fresenius Kabi USA, LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 2, 2022 |
| Hikma Pharmaceuticals USA Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 27, 2022 |
| Meitheal Pharmaceuticals Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 26, 2022 |
| Ningbo Shuangcheng Pharmaceutical Co., Ltd | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | December 17, 2025 |
| NorthStar RxLLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | November 1, 2024 |
| Novadoz Pharmaceuticals LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 26, 2022 |
| Pharmascience Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 2, 2022 |
| Qilu Pharmaceutical Co., Ltd. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 2, 2022 |
| Sagent Pharmaceuticals | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 15, 2025 |
| Shilpa Medicare Limited | 1 | injection | New drug applications (NDA) | September 25, 2024 |
| Sintetica US LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 15, 2023 |
| Somerset Therapeutics, LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | April 29, 2025 |
| Takeda Pharmaceuticals America, Inc. | 1 | injection, powder, lyophilized, for solution | New drug applications (NDA) | May 13, 2003 |
| Waverley Pharma Inc | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | June 19, 2018 |
| Zydus Lifesciences Limited | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 2, 2022 |
| Zydus Pharmaceuticals USA Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 2, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, lyophilized, for solution | 29 | 87.9% |
| Injection | 4 | 12.1% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 26 | 78.8% |
| New drug applications (NDA) | 7 | 21.2% |
Pharmacologic classes
| Class | Products |
|---|---|
| Proteasome Inhibitor | 33 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.